On the one hand, the inhibition of PNP was previously identified as a promising therapeutic strategy in T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL)32. The gene discussed is PNP; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.